A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions
To evaluate the bioequivalence of two formulations of Sarpogrelate HCl 300mg after a single oral dose administration in healthy volunteers under fasting conditions
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
38
a single oral dose administration in healthy volunteers under fasting condition
Daewoong pharmatceutical
Seoul, South Korea
Maximum Plasma Concentration
Maximum Plasma Concentration
Time frame: 0~24hours
Area under the plasma concentration versus time curve
Area under the plasma concentration versus time curve
Time frame: 0~24hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.